dc.contributor.author
Sahin, Elvan
dc.contributor.author
Hawro, Marlena
dc.contributor.author
Weller, Karsten
dc.contributor.author
Sabat, Robert
dc.contributor.author
Philipp, Sandra
dc.contributor.author
Kokolakis, Georgios
dc.contributor.author
Christou, Demetrios
dc.contributor.author
Metz, Martin
dc.contributor.author
Maurer, Marcus
dc.contributor.author
Hawro, Tomasz
dc.date.accessioned
2022-11-28T16:44:16Z
dc.date.available
2022-11-28T16:44:16Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/37075
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-36789
dc.description.abstract
Background: Sleep, which is crucial for restoring of physiological functions and health, is reportedly impaired in psoriasis. The role of different potential sleep confounding factors, including detailed pruritus characteristics, and the complex interplay between psychological variables (anxiety and depression), pruritus and sleep disturbance in psoriasis remain insufficiently investigated.
Objectives: To investigate sleep characteristics and to identify clinical, demographic and psychological factors associated with sleep disturbance in psoriasis.
Methods: This cross-sectional study included 334 psoriasis patients (response rate 86%) and 126 control subjects (response rate 82%). Measures included sleep quality [Pittsburgh Sleep Quality Index (PSQI)], psoriasis severity, pruritus characteristics, including average pruritus intensity [visual analogue scale (VAS)], severity of comorbidities, anxiety and depression (Hospital Anxiety and Depression Scale - HADS) and quality of life (Dermatology Life Quality Index - DLQI, and Short Form 12 - SF12).
Results: Fifty-nine per cent of patients and 34% of control subjects (P < 0.001) suffered from sleep disturbance (PSQI > 5). Patients slept 1 h less than control subjects (median 6 vs. 7 h, P < 0.001). Patients without pruritus had less impaired sleep (global PSQI) than patients with strong (P < 0.001) and very strong pruritus (P < 0.001). Anxiety (HADS-A) and depression (HADS-D) levels were the strongest predictors of sleep impairment, followed by pruritus exacerbation at night, age, female sex, pruritus exacerbation in the morning, average pruritus intensity (VAS), diagnosed depression and gastroesophageal reflux disease, altogether explaining 32%-37% of the variance in global sleep quality. Both anxiety (HADS-A) and depression (HADS-D) were significant mediators explaining the association between pruritus intensity (VAS) and sleep impairment in 42% and 37% respectively.
Conclusions: Sleep disturbance in patients with psoriasis is highly prevalent. Patients with psoriasis should be assessed for sleep impairment, pruritus, anxiety and depression. Reduction in pruritus should be considered as an important therapeutic goal, along with therapies aimed at reducing anxiety and depression.
en
dc.rights.uri
https://creativecommons.org/licenses/by-nc/4.0/
dc.subject
Sleep Wake Disorders
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Prevalence and factors associated with sleep disturbance in adult patients with psoriasis
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1111/jdv.17917
dcterms.bibliographicCitation.journaltitle
Journal of the European Academy of Dermatology and Venereology
dcterms.bibliographicCitation.number
5
dcterms.bibliographicCitation.originalpublishername
Wiley
dcterms.bibliographicCitation.pagestart
688
dcterms.bibliographicCitation.pageend
697
dcterms.bibliographicCitation.volume
36
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
DEAL Wiley
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
35020226
dcterms.isPartOf.issn
0926-9959
dcterms.isPartOf.eissn
1468-3083